AGI Dermatics Closes $5 Million Investment Round

FREEPORT, N.Y., April 8, 2008 /PRNewswire/ -- AGI Dermatics, the biopharmaceutical company focused on the development and sale of skincare products utilizing DNA repair technology, announced today it closed a $5 million investment round led by existing investor Trevi Health Ventures and new investor Spring Mountain Capital.

The new capital is being used to fund the continued growth of the Remergent brand skincare, including the launch of four new products. The Remergent skincare line preserves and restores healthy skin utilizing DNA repair enzymes delivered to the skin through a proprietary liposome delivery system.

"We are gratified that our current investors have renewed their commitment to the growth of our company brand and are pleased that a significant new investor has joined us in our vision of the opportunity in dermatology and skincare in the coming years," said Daniel Yarosh, Ph.D., President of AGI Dermatics. "This investment provides us with a platform to expand the reach of our technology into the marketplace."

About AGI Dermatics

AGI Dermatics is the biopharmaceutical company that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system and its proprietary brand, Remergent(R). Advancing the link between science and beauty, the company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in dozens of peer-reviewed scientific and medical journals. www.agiderm.com

SOURCE AGI Dermatics

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.